Appropriateness of psychotropic medication use in a cohort of adolescents with intellectual disability in Queensland, Australia

被引:6
|
作者
Song, Menghuan [1 ]
Ware, Robert S. [1 ,2 ]
Doan, Tan N. [3 ]
McPherson, Lyn [1 ,2 ]
Trollor, Julian N. [4 ]
Harley, David [1 ]
机构
[1] Univ Queensland, Mater Hosp, Queensland Ctr Intellectual & Dev Disabil, Mater Res Inst, Brisbane, Qld, Australia
[2] Griffith Univ, Menzies Hlth Inst Queensland, Nathan, Qld, Australia
[3] Univ Melbourne, Dept Med, Royal Melbourne Hosp, Melbourne, Vic, Australia
[4] Univ New South Wales, Dept Dev Disabil Neuropsychiat, Fac Med, Sydney, NSW, Australia
来源
BJPSYCH OPEN | 2020年 / 6卷 / 06期
关键词
Psychotropic drugs; intellectual disability; off-label use; inappropriate prescribing; adolescent; ADULTS; DRUGS;
D O I
10.1192/bjo.2020.125
中图分类号
R749 [精神病学];
学科分类号
100205 ;
摘要
Background Psychotropic medications are sometimes used off-label and inappropriately. This may cause harm to adolescents with intellectual disability. However, few studies have analysed off-label or inappropriate prescribing to this group. Aims To examine the appropriateness of psychotropic prescribing to adolescents with intellectual disability living in the community in south-east Queensland, Australia. Method Off-label medication use was determined based on whether the recorded medical condition treated was approved by the Australian Therapeutic Goods Administration. Clinical appropriateness of medication use was determined based on published guidelines and clinical opinion of two authors who specialise in developmental disability medicine (J.N.T. and D.H.). Results We followed 429 adolescents for a median of 4.2 years. A total of 107 participants (24.9%) were prescribed psychotropic medications on at least one occasion. Of these, 88 (82.2%) were prescribed their medication off-label or inappropriately at least once. Off-label or inappropriate use were most commonly associated with challenging behaviours. Conclusions Off-label or inappropriate use of psychotropic medications was common, especially for the management of challenging behaviours. Clinical decision-making accounts for individual patient factors and is made based on clinical experience as well as scientific evidence, whereas label indications are developed for regulatory purposes and, although appropriate at a population level, cannot encompass the foregoing considerations. Education for clinicians and other staff caring for people with intellectual disability, and a patient-centred approach to prescribing with involvement of families should encourage appropriate prescribing. The effect of the National Disability Insurance Scheme on the appropriateness of psychotropic medication prescribing should be investigated.
引用
收藏
页数:6
相关论文
共 50 条
  • [1] Psychotropic medication use in adults with intellectual disability in Queensland, Australia, from 1999 to 2015: a cohort study
    Song, M.
    Ware, R.
    Doan, T. N.
    Harley, D.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2020, 64 (01) : 45 - 56
  • [2] PSYCHOTROPIC MEDICATION USE IN ADULTS WITH INTELLECTUAL DISABILITY IN QUEENSLAND, AUSTRALIA FROM 1999 TO 2016
    Song, M.
    Harley, D.
    Ware, R.
    Doan, T.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 691 - 691
  • [3] Psychotropic medication use in adolescents with intellectual disability living in the community
    Doan, Tan
    Ware, Robert
    McPherson, Lyn
    van Dooren, Kate
    Bain, Christopher
    Carrington, Suzanne
    Einfeld, Stewart
    Tonge, Bruce
    Lennox, Nicholas
    PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, 2014, 23 (01) : 69 - 76
  • [4] Prevalence of Psychotropic Medication Use and Psychotropic Polypharmacy in Autistic Adults With or Without Intellectual Disability
    Yoshida, Kazunari
    Lunsky, Yona
    Mueller, Daniel J.
    Desarkar, Pushpal
    JOURNAL OF AUTISM AND DEVELOPMENTAL DISORDERS, 2025, 55 (02) : 457 - 471
  • [5] PRESCRIBING PSYCHOTROPIC MEDICATION TO PEOPLE WITH INTELLECTUAL DISABILITY
    Bennett, C.
    AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY, 2018, 52 : 76 - 76
  • [6] Use of psychotropic drugs in children, adolescents and subjects with intellectual disability: a review
    Lazzeretti, Lisa
    Pracucci, Chiara
    Benni, Laura
    Godini, Lucia
    Talamba, Gabriela Alina
    Faravelli, Carlo
    RIVISTA DI PSICHIATRIA, 2011, 46 (01) : 1 - 17
  • [7] QUALITATIVE EXPLORATION OF PSYCHOTROPIC MEDICATION PRESCRIBING FOR ADULTS WITH INTELLECTUAL DISABILITY
    Sheehan, R.
    Strydom, A.
    Hassiotis, A.
    Morant, N.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2019, 63 (07) : 678 - 678
  • [8] Receipt of psychotropic medication by people with intellectual disability in residential settings
    Robertson, J
    Emerson, E
    Gregory, N
    Hatton, C
    Kessissoglou, S
    Hallam, A
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2000, 44 : 666 - 676
  • [9] Prevalence and characteristics of psychotropic drug use in institutionalized children and adolescents with mild intellectual disability
    Scheifes, Arlette
    de Jong, Daniel
    Stolker, Joost Jan
    Nijman, Henk L. I.
    Egberts, Toine C. G.
    Heerdink, Eibert R.
    RESEARCH IN DEVELOPMENTAL DISABILITIES, 2013, 34 (10) : 3159 - 3167
  • [10] Problem behaviours and psychotropic medication use in intellectual disability: a multinational cross-sectional survey
    Perry, B. I.
    Kwok, H. F.
    Mendis, J.
    Purandare, K.
    Wijeratne, A.
    Manjubhashini, S.
    Dasari, M.
    Esan, F.
    Gunaratna, I.
    Naseem, R. A.
    Hoare, S.
    Chester, V.
    Roy, A.
    Devapriam, J.
    Alexander, R.
    Cooray, S. E.
    JOURNAL OF INTELLECTUAL DISABILITY RESEARCH, 2018, 62 (02) : 140 - 149